Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 182

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression

Open access
Nobili, Stefania, Landini, Ida, Mazzei, Teresita, Mini, Enrico·2012·Medicinal Research Reviews

Abstract

Multidrug resistance (MDR) is a major obstacle to the effective treatment of cancer. Cellular overproduction of P‐glycoprotein (P‐gp), which acts as an efflux pump for various anticancer drugs (e.g. anthracyclines, Vinca alkaloids, taxanes, epipodophyllotoxins, and some of the newer antitumor drugs) is one of the more relevant mechanisms underlying MDR. P‐gp belongs to the superfamily of ATP‐binding cassette transporters and is encoded by the ABCB1 gene. Its overexpression in cancer cells has become a therapeutic target for circumventing MDR. As an alternative to the classical pharmacological strategy of the coadministration of pump inhibitors and cytotoxic substrates of P‐gp and to other approaches applied in experimental tumor models (e.g. P‐gp‐targeting antibodies, ABCB1 gene silencing strategies, and transcriptional modulators) and in the clinical setting (e.g. incapsulation of P‐gp substrate anticancer drugs into liposomes or nanoparticles), a more intriguing strategy for circumventing MDR is represented by the development of new anticancer drugs which are not substrates of P‐gp (e.g. epothilones, second‐ and third‐generation taxanes and other microtubule modulators, topoisomerase inhibitors). Some of these drugs have already been tested in clinical trials and, in most of cases, show relevant activity in patients previously treated with anticancer agents which are substrates of P‐gp. Of these drugs, ixabepilone, an epothilone, was approved in the United States for the treatment of breast cancer patients pretreated with an anthracycline and a taxane. Another innovative approach is the use of molecules whose activity takes advantage of the overexpression of P‐gp. The possibility of overcoming MDR using the latter two approaches is reviewed herein. © 2011 Wiley Periodicals, Inc. Med Res Rev

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/med.20239

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 182

Metadata

Authors
Nobili, S., Landini, I., Mazzei, T., & Mini, E.
Venue
Medicinal Research Reviews
Publisher
Wiley
Published
2011-03-03
Volume
32
Issue
6
Pages
1220-1262
ISSN
  • 0198-6325 (ISSN-L)
  • 1098-1128
OpenAlex
W1517036148
Cited by
182
References
5
FWCI
6.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression. https://app.cochat.ai/papers/10.1002/med.20239
The paper
Nobili, S., Landini, I., Mazzei, T., & Mini, E. (2012). Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression. Medicinal Research Reviews. https://doi.org/10.1002/med.20239

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.